Healthcare entity
medical-devices is the sole category represented across all 3 tracked stories. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. Abbott Laboratories is most often covered alongside Cologuard, which appears in 1 of these 3 stories.
Last mentioned: 1d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
medical-devices is the sole category represented across all 3 tracked stories. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. Abbott Laboratories is most often covered alongside Cologuard, which appears in 1 of these 3 stories. The 153-day window averages about 0.1 stories each week. Their average consequence score of 5.7 runs below the beat's 6 for that window. We currently track 3 Healthcare stories that mention Abbott Laboratories, published between March 23, 2026 and August 22, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 599 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Abbott Laboratories. Shared-story counts are live from our verified record — not editorial picks.
MiniMed scheduled to report fiscal Q1 2027 results
MiniMed Group will report its fiscal Q1 2027 results, the first earnings check after the MiniMed Flex U.S. launch.
MiniMed announces U.S. commercial shipping of MiniMed Flex with Abbott Instinct
MiniMed Group says its Flex automated insulin delivery system is now shipping in the U.S. integrated with Abbott's Instinct 15-day continuous glucose sensor.
The Abbott-MiniMed Flex integration is now shipping in the U.S., pairing Abbott's 15-day Instinct sensor with MiniMed's smallest app-controlled insulin pump. Clinicians and health systems gain a real-world data point of 80% Time in Range, while payers will weigh the combined system's value against entrenched CGM and AID competitors.
Source: insidermonkey.com · finance.yahoo.com
Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
As global diabetes prevalence reaches record highs, the shift toward localized medical device production is driving a surge in glucometer manufacturing plant investments for 2026. This briefing analyzes the cost structures, regulatory hurdles, and technological requirements for establishing high-volume diagnostic production facilities.
Source: openpr.com · openpr.com
Abbott Laboratories is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
